News

Sygnature takes immense pride in its numerous accomplishments, fruitful research partnerships, and well-deserved awards. It is with great pleasure that we share these remarkable achievements at every available opportunity. Contained herein, you will have the opportunity to explore and be informed about the latest and most thrilling advancements taking place within our organization.

Filter by:

News

Sygnature Discovery has Chosen Elsevier as New Preferred Partner to Empower its Global Team of Chemists

READ ARTICLE

News

Sygnature Discovery Strengthens Leadership Team with Amira Modi as Chief Operating Officer and Board Member

READ ARTICLE

News

Sygnature Discovery Unlocks Life-Changing Treatment Options with New Human Disease Modeling Platform

READ ARTICLE

News

Sygnature Discovery boosts North American growth with new General Manager

READ ARTICLE

News

Sygnature Discovery Receives EcoVadis Award For Sustainable Excellence

READ ARTICLE

News

Sygnature Discovery goes for global industry recognition with Chief Scientific Officer hire

READ ARTICLE

News

First patients dosed in Phase 1a clinical trial of UCL-backed G-Quadruplex (G4) targeting treatment for solid tumors, including pancreatic cancer

READ ARTICLE

News

Sygnature Discovery Appoints Industry Leaders To Board Of Directors

READ ARTICLE

News

Sygnature Discovery invests £3.75M in Compound Management to provide cutting-edge hit finding capabilities to pharma and biotechnology customers

READ ARTICLE

News

Sygnature Discovery collaborates with Axol Bioscience to utilize ​human ​iPSC-derived microglial cells in high-content imaging drug discovery screening workflows.

READ ARTICLE

News Targeted Protein Degradation

Sygnature Discovery and UBE Corporation successfully identify potent SHP2 degrader compounds

READ ARTICLE

News

Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment

READ ARTICLE
MORE...